Although direct evidence for tetradioxin in ARDS is lacking, its dual targeting of SMARCD3 and TCN1 suggests it may regulate inflammatory and metabolic pathways pertinent to ARDS. Here, SMARCD3 is linked to acute respiratory distress syndrome.